How the FDA Regulates Peptides

How the FDA Regulates Peptides: A Growing Regulatory Gray Zone Under Scrutiny

The Food and Drug Administration's oversight of peptide-based products has come under renewed examination, as a new analysis from the Johns Hopkins Bloomberg School of Public Health lays out the complex and often confusing regulatory landscape governing this fast-growing category of compounds. The report arrives at a moment when peptides—short chains of amino acids used in everything from diabetes and weight-loss drugs to unproven "research chemical" injectables sold online—are drawing increasing attention from regulators, lawmakers, and public health experts.

According to the Johns Hopkins Bloomberg School of Public Health, the FDA's regulatory framework for peptides is fragmented, relying on multiple, sometimes overlapping pathways depending on how a peptide is marketed, manufactured, and sold. That fragmentation, the source indicates, has created openings that some manufacturers and sellers exploit to skirt the agency's more rigorous drug-approval requirements.

Why Peptide Regulation Matters Now

Peptides have exploded in popularity over the past several years, driven largely by the success of FDA-approved GLP-1 drugs like semaglutide and tirzepatide, which are themselves peptide-based medications. That mainstream success has fueled a parallel marketplace of peptides marketed for muscle growth, anti-aging, fat loss, and other purposes—many of which have never gone through FDA's formal approval process for safety and efficacy.

This dual reality is central to why the regulatory question matters. On one hand, the FDA has approved a growing list of peptide therapeutics that meet rigorous clinical trial standards. On the other, a largely unregulated market has emerged for peptides sold as "research use only" chemicals, dietary supplements, or through compounding pharmacies, often reaching consumers without the safety oversight typically required of prescription drugs.

The Multiple Pathways the FDA Uses

Peptides can enter the market—or attempt to—through several distinct regulatory channels, each with different levels of scrutiny:

• New Drug Applications (NDAs): Peptides intended for therapeutic use as prescription drugs must undergo the FDA's standard clinical trial and approval process, the same pathway required for traditional pharmaceuticals.
• Compounding pharmacies (503A and 503B): Some peptides have been compounded by specialty pharmacies under provisions that allow customized formulations, though the FDA has increasingly restricted which peptides may legally be compounded.
• Bulk drug substances lists: The FDA maintains lists determining which substances compounders may legally use, and the agency has moved to exclude certain popular peptides—including some GLP-1 compounds and others like BPC-157—from these lists, citing safety concerns and insufficient data.
• Research-use-only labeling: A significant share of peptides marketed online are sold with disclaimers stating they are intended for laboratory research, not human use—a labeling loophole that public health experts say is frequently ignored by both sellers and buyers.
• Dietary supplements: Some peptide products attempt to market themselves under supplement regulations, which carry substantially lower safety and efficacy thresholds than drug approval.

This patchwork, the Johns Hopkins analysis suggests, leaves consumers with little clear guidance about which peptide products have been vetted for safety and which have not.

Regulatory Implications for the Industry

For pharmaceutical companies, compounding pharmacies, and peptide manufacturers, the FDA's fragmented approach creates both risk and opportunity. Companies pursuing full drug approval face a lengthy, expensive process, but gain legal certainty and market exclusivity. Those operating in the compounding or research-chemical space face a shifting regulatory environment, as the FDA continues to reassess which substances qualify for bulk drug substance lists and which enforcement actions it will pursue against non-compliant sellers.

The agency has, in recent years, issued warning letters and taken enforcement action against companies selling peptides with unsubstantiated health claims or without proper labeling. However, critics argue that enforcement has not kept pace with the rapid proliferation of online sellers, many of which operate outside traditional pharmaceutical distribution channels entirely.

What This Means for Readers

For consumers, patients, and industry stakeholders, the current regulatory environment carries several practical implications:

• Peptides sold as "research chemicals" have not been evaluated by the FDA for human safety or efficacy, regardless of how they are marketed online.
• FDA-approved peptide drugs undergo the same clinical trial scrutiny as any other prescription medication, offering a meaningfully different safety profile than unregulated alternatives.
• Compounded peptides occupy a middle ground, subject to pharmacy oversight but not the same premarket approval standards as branded drugs.
• The regulatory status of a given peptide can change quickly, as the FDA updates bulk drug substance lists and issues new guidance.
• Consumers should be cautious of products making therapeutic claims without FDA approval, particularly those purchased outside licensed pharmacy channels.

What to Watch Next

Observers expect the FDA to continue refining its bulk drug substances lists and to face pressure from both industry groups seeking clearer rules and public health advocates pushing for tighter enforcement against unregulated sellers. Congressional interest in compounding practices, particularly following past controversies involving GLP-1 shortages and compounded versions of branded weight-loss drugs, may also shape future rulemaking.

As the peptide market continues to expand, stakeholders across the pharmaceutical, compounding, and retail supplement industries will likely see continued regulatory adjustments in the months ahead. Readers seeking the most current guidance should consult FDA.gov directly, as agency policy in this area remains in flux.

This article is intended for informational purposes only and does not constitute legal, medical, or regulatory advice. Readers should consult qualified professionals and official FDA resources for guidance specific to their circumstances.